期刊文献+

益肾降浊冲剂治疗慢性肾衰竭的临床观察及对血清瘦素的影响 被引量:13

Clinical Effect of Soluble Granules Yishenjiangzhuo for Chronic Renal Failure and Effect to Serum Leptin
下载PDF
导出
摘要 目的:观察益肾降浊冲剂治疗慢性肾衰竭(CRF)的临床疗效及治疗前后血清瘦素(leptin)水平的变化情况。方法:选择CRF患者40例,随机分为治疗组20例,对照组20例。治疗组用益肾降浊冲剂治疗,对照组用单味大黄治疗,观察尿素氮、肌酐、肌酐清除率、白蛋白、血红蛋白、瘦素等指标及临床症状的变化。结果:治疗组临床疗效优于对照组(P<0.05),治疗组降低血清瘦素水平明显优于对照组(P<0.01),患者血清瘦素与肌酐清除率显著负相关、与血肌酐有显著正相关(P<0.01)。治疗组改善CRF患者临床证候疗效优于对照组(P<0.01)。结论:益肾降浊冲剂对CRF辨证属脾肾气虚证为主者,起到改善症状,改善肾功能并能延缓CRF进展;临床疗效优于单味大黄。益肾降浊冲剂能降低CRF血清瘦素水平,可能是其获得疗效的机制之一。 Objective:To observe the clinical result of Soluble Granules Yishenjiangzhuo in patients with chronic renal failure (CRF) and the change of serum leptin level. Methods: According to the standard in Chinese journal of internal medicine and national symposium of TCM, 40 patients with CRF were divided into treatment group and contrast group at random, treatment group is 20 case and contrast group is also 20 case, Patients of treatment group took the Yishenjingzhou decoction, Patients of contrast group took the Chinese Rhubarb. Observe the change of Blood urea nitrogen(BUN) .serum creatinine (ser) .clearance of endogenous crea- tinine(Ccr) .Albumin.Hemoglobin. serum Leptin levels and symptom in before and after therapy. Serum Leptin level were detected by radioimmunoassay (RIA) method. Results: The therapeutic efficacy of treatment group on Yisbenjingzhou decoction is much better than that of contrast group (P〈0.05). The Serum Leptin level was obviously reduced after Soluble Granules Yishenjiangzhuo therapy (P〈 0.01 ). The analysis of correlation showed that 'the serum Leptin level of patient is negatively correlated to clearance of endogenous creatinine and positively correlated to the level of serum creatinine. Conclusion:Through the function of supplement and boost the spleen and kidney, and discharge turbidity and dispel stasis, Soluble Granules Yishenjiangzhuo can improve renal function and lighten clinical symptom and delay the development of CRF with spleen- kidney qi vacuity. Soluble Granules Yishenjiangzhuo can decrease the Leptin level in patients with CRF, which may be one of mechanism of its effect.
出处 《中国中西医结合肾病杂志》 2007年第2期84-86,共3页 Chinese Journal of Integrated Traditional and Western Nephrology
基金 福建省科技厅基金资助项目(No2000Z154)
关键词 益肾降浊冲剂 慢性肾衰竭 瘦素 临床观察 Yishenjiangzhuo Chronic renal failure Leptin Clinical effect
  • 相关文献

参考文献5

  • 1王海燕.肾脏病学[M].北京:人民卫生出版社,2001.1442-1446.
  • 2郑筱萸.中药新药治疗慢性肾衰竭的临床研究指导原则.北京:中国医药科技出版社,2002.163-168.
  • 3Yong GA,Woodrow G,Kendall S,et al.Increased plasma leptin/fat ration in patients with chronic renal failure:a cause of malnutrition.Nephrol Dial Transplant,1997,12(11):2318-2323.
  • 4刘必成,周秋根.慢性肾功能不全肾脏保护治疗研究进展[J].江苏医药,2002,28(4):293-295. 被引量:2
  • 5Johansen KL,Mulligan K,Tai V.Leptin body composition and indices of malnutrition in patients on dialysis.J Am Soc Nephrol,1998,9(6):1080-1084.

二级参考文献16

  • 1[1]Romero F,Rodriguez-Iturbe B,Parra G,et al.Mycophenolate mofetil prevents the progressive renal failure induced by 5/6 renal ablation in rats.Kidney Int,1999,55:945-955.
  • 2[2]Abbate M,Zoja C,Rottoli D,et al.Antiproteinuric therapy while preventing the abnormal protein trafficc in proximal tubule abrogates protein-and complement-dependent interstitial inflammation in experimental renal disease.J Am Soc Nephrol,1999,10:804-813.
  • 3[3]Mezzano S,Drognett M,Burgos E,et al.Overexpression of chemokines,fibrogenic cytokines,and myofibroblasts in human membranous nephropathy.Kidney int,2000,57:147-158.
  • 4[4]Brenner B,Taal M.Renoprotective benefits of RAS inhibition:From ACEi to angiotensin Ⅱ antagonists.Kidney Int,2000,57.1803-1817.
  • 5[5]Remuzzi G,Ruggenenti P,Benigni A.Understanding the nature of renal disease progression:In proteinuric nephropathies enhanced glomerular protein traffic contributes to interstitial inflammation and renal scarring.Kidney Int,1997,51:2-15.
  • 6[6]Fogo A.The role of angiotensin Ⅱ and plasminogen activator inhibitor-1 in progressive glomerulosclerosis.Am J Kidney Dis,2000,135:179-188.
  • 7[7]Leehey DJ,Singh AK,Alavi N,et al.Role of angiotensin Ⅱ in diabetic nephropathy.Kidney Int,2000,58(Suppl 77):93-98.
  • 8[8]Hebert LA,Greene T,Levey A,et al.High urine volume (UV) and how urine osmolality(Uosm)are risk factors for faster progression of renal disease(RD),especially in polycystic kidney disease(PKD) patients.J Am Soc Nephrol,2000,11:148A.
  • 9[9]Oda H,Keane W.Recent advances in statins and the kidney.Kidney Int,1999,56(Suppl):2-5.
  • 10[10]Hebert LA,Wilmer WA,Falkenhain ME,et al.Renoprotection:One or many therapies? Kidney Int,2001,59:1211-1226.

共引文献22

同被引文献143

引证文献13

二级引证文献48

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部